Fig. 3From: Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysisAHAs included in baseline regimen and with continued use in follow-up (N = 4017). Medications included in the AHA regimen at the time of the canagliflozin fill were further assessed in the follow-up period for evidence of discontinuation. Treatment was considered discontinued if a ≥60 day gap in therapy was observed. DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1Back to article page